# Nervonic acid confers neuroprotection in a zebrafish model of diabetic neuropathy by promoting myelin repair and metabolic modulation

**Authors:** Huan Ge, Mingzhu Dai, Qinwen Wang, Bingbing Cao, Ximin Zhu, Jie Guo, Tao Zhang, Shasha Wang, Yiqiao Xu, Lushan Yu

PMC · DOI: 10.3389/fphar.2026.1721486 · Frontiers in Pharmacology · 2026-02-18

## TL;DR

Nervonic acid protects against diabetic neuropathy in zebrafish by improving myelin and reducing inflammation and oxidative stress.

## Contribution

This study reveals that nervonic acid promotes myelin repair and metabolic modulation in a zebrafish model of diabetic neuropathy.

## Key findings

- NA preserved myelin integrity and reduced neutrophil infiltration and ROS levels in diabetic zebrafish.
- NA upregulated myelin-related genes and downregulated pro-inflammatory cytokines.
- NA restored key metabolites in purine, energy, vitamin B6, and redox pathways disrupted by diabetes.

## Abstract

Diabetic neuropathy (DN) is one of the most common and debilitating complications of type 2 diabetes mellitus (T2DM), yet effective therapeutic strategies remain limited. Nervonic acid (NA) is recognized for its neuroprotective and anti-inflammatory properties. However, its role in DN has not been fully elucidated. In this study, we investigated the protective effects of NA against T2DM-induced DN using a zebrafish model and explored the underlying molecular mechanisms.

T2DM was induced in zebrafish larvae through a high-fat, high-glucose diet combined with a low dose of streptozotocin. Larvae were subsequently treated with NA at concentrations of 125, 250, or 500 μg/mL. Motor function, myelin integrity, neutrophil infiltration, and reactive oxygen species (ROS) levels were evaluated using fluorescence imaging and histological staining. Gene expression analysis was performed by quantitative real-time PCR. Metabolomics coupled with KEGG enrichment analysis was applied to identify NA-regulated metabolic pathways.

NA significantly preserved myelin integrity, reduced neutrophil infiltration, and lowered ROS levels in DN zebrafish. Expression of myelin-related genes (mbpa and mpz) was upregulated, while pro-inflammatory cytokines were downregulated following NA treatment. Metabolomic profiling revealed that NA reversed diabetes-associated dysregulation in purine metabolism, energy metabolism, vitamin B6 pathways, and redox homeostasis. Key metabolites including guanosine monophosphate, adenosine triphosphate, pyridoxal 5′-phosphate, and L-glutathione were markedly restored toward normal levels.

These findings demonstrate that NA confers robust neuroprotection in DN by alleviating inflammation and oxidative stress, preserving neuronal structure and function, and reprogramming key metabolic pathways.

## Linked entities

- **Genes:** mbpa (myelin basic protein a) [NCBI Gene 326281], MPZ (myelin protein zero) [NCBI Gene 4359]
- **Chemicals:** nervonic acid (PubChem CID 5281120), guanosine monophosphate (PubChem CID 135398631), adenosine triphosphate (PubChem CID 5957), pyridoxal 5′-phosphate (PubChem CID 1051), L-glutathione (PubChem CID 65359), streptozotocin (PubChem CID 29327)
- **Diseases:** diabetic neuropathy (MONDO:0006626), type 2 diabetes mellitus (MONDO:0005148)
- **Species:** Danio rerio (taxon 7955)

## Full-text entities

- **Genes:** mnx1 (motor neuron and pancreas homeobox 1) [NCBI Gene 405399] {aka hlxb9, zgc:112174}, mpz (myelin protein zero) [NCBI Gene 114417] {aka p0, sc:d0186, wu:fc04b11, wu:fi30g06, zgc:103775}, vip (vasoactive intestinal peptide) [NCBI Gene 795653] {aka vip1, zgc:171463}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, mbpa (myelin basic protein a) [NCBI Gene 326281] {aka cb274, fj33b11, mbp, wu:fj33b11, wu:fq15b02, zgc:136630}, il6 (interleukin 6 (interferon, beta 2)) [NCBI Gene 100885851], il1b (interleukin 1, beta) [NCBI Gene 405770] {aka il1-b, zgc:111873}, actb1 (actin, beta 1) [NCBI Gene 57934] {aka ACTB, B-ACTZF, actba, bact, bactin1, bactzf}, crp-5 [NCBI Gene 751795], MPZ (myelin protein zero) [NCBI Gene 4359] {aka CMT1, CMT1B, CMT2I, CMT2J, CMT4E, CMTDI3}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, ins (preproinsulin) [NCBI Gene 30262] {aka zgc:109842}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, tnfa (tumor necrosis factor a (TNF superfamily, member 2)) [NCBI Gene 405785], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, mpx (myeloid-specific peroxidase) [NCBI Gene 337514] {aka drf, fj80f04, mpo, wu:fj80f04}, MBP (myelin basic protein) [NCBI Gene 4155]
- **Diseases:** cardiovascular complications (MESH:D002318), DN (MESH:D003929), numbness (MESH:D006987), cytotoxicity (MESH:D064420), Insulin resistance (MESH:D007333), loss of coordination (MESH:D001259), abnormal myelination (MESH:D003711), hyperglycemic (MESH:D006944), hyperinsulinemia (MESH:D006946), nerve damage (MESH:D000080902), immune dysregulation (OMIM:614878), myelin damage (MESH:D020279), allodynia (MESH:D006930), neuropathies (MESH:D009422), axonal damage (MESH:D001480), motor impairments (MESH:D000068079), T2DM (MESH:D003924), axonal degeneration (MESH:D009410), Proinflammatory cytokines (MESH:D000080424), nephropathy (MESH:D007674), peripheral nerve damage (MESH:D010523), tingling (MESH:D010292), type 1 diabetes mellitus (MESH:D003922), impaired locomotor activity (MESH:D001523), impaired (MESH:D060825), neurotoxicity (MESH:D020258), neural damage (MESH:D015441), weakness (MESH:D018908), DM (MESH:D003920), sensory deficits (MESH:D012678), neuropathic symptoms (MESH:D001750), behavioral deficits (MESH:D019958), neurological complications (MESH:D002493), neuroinflammation (MESH:D000090862), pancreatic beta-cell injury (MESH:D010195), wound (MESH:D014947), demyelinating and neurodegenerative conditions (MESH:D019636), Inflammation (MESH:D007249), hyperglycemia (MESH:D006943), impaired nerve conduction (MESH:D019955), pain (MESH:D010146), dyslipidemia (MESH:D050171), mitochondrial dysfunction (MESH:D028361), neurological disorders (MESH:D009461), endoneurial ischemia (MESH:D007511), metabolic diseases (MESH:D008659), hyperactivity (MESH:D006948), Purine metabolism disturbances (MESH:D011686), damage (MESH:D020263), retinopathy (MESH:D058437)
- **Chemicals:** guanine nucleotide (MESH:D006150), amino acid (MESH:D000596), starch (MESH:D013213), monounsaturated fatty acid (MESH:D005229), carbohydrate (MESH:D002241), acarbose (MESH:D020909), 4-Chloro-phenylalanine (-), sodium citrate (MESH:D000077559), vitamin B6 (MESH:D025101), sphingolipids (MESH:D013107), PLP (MESH:D011732), Glucose (MESH:D005947), DMSO (MESH:D004121), ROS (MESH:D017382), tricaine (MESH:C003636), ATP (MESH:D000255), citrate (MESH:D019343), L-glutathione (MESH:D005978), bicinchoninic acid (MESH:C047117), sucrose (MESH:D013395), lipid (MESH:D008055), Purine (MESH:C030985), agarose (MESH:D012685), Pioglitazone (MESH:D000077205), lactose (MESH:D007785), uric acid (MESH:D014527), acetonitrile (MESH:C032159), GTP (MESH:D006160), methanol (MESH:D000432), saline (MESH:D012965), GMP (MESH:D006157), formic acid (MESH:C030544), NA (MESH:C013147), Blood glucose (MESH:D001786), advanced glycation end-products (MESH:D017127), water (MESH:D014867), nucleotide (MESH:D009711), STZ (MESH:D013311)
- **Species:** Homo sapiens (human, species) [taxon 9606], Danio rerio (leopard danio, species) [taxon 7955]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957253/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957253/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957253/full.md

---
Source: https://tomesphere.com/paper/PMC12957253